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Prior studies suggest that 6 percent of opioid-naive patients continue to fill opioid prescriptions more than 3 months after undergoing major and minor surgical procedures. 9 Moreover, opioid misuse is higher among patients with obesity and following bariatric surgery, 12, 13 attributable in part to the prevalence of chronic pain and comorbid psychiatric conditions. [14] [15] [16] [17] Body contouring procedures may further contribute to opioid use in these patients, and use of these procedures continues to rise. 18 To date, however, patterns of opioid use following body contouring procedures have not been well described, and the risk factors associated with new persistent use remain undefined.
Given the combined risk factors of psychiatric comorbidities, high rates of obesity and bariatric surgery, and the potential for developing persistent pain after surgery, we hypothesized that body contouring patients would similarly develop persistent opioid use after surgery. Furthermore, we hypothesized that prescribing patterns would be marked by high-risk occurrences, such as high daily doses, overlapping prescriptions, and concurrent prescribing with benzodiazepines. To evaluate this, we analyzed a claims-based data set to measure persistent opioid use after common body contouring procedures and potential risk factors for the development of persistent use.
PATIENTS AND METHODS

Data Source and Study Cohort
After institutional review board exemption, we analyzed private insurance claims from Clinformatics Data Mart (OptumInsight, Eden Prairie, Minn.), a national claims database. OptumInsight contains records for more than 140 million enrollees and includes data on patient demographics, insurance coverage, use of inpatient and outpatient services, and outpatient pharmacy claims. To obtain our cohort, we included all patients between the ages of 18 and 64 years who underwent a body contouring surgical procedure between January 1, 2002, and September 30, 2014. Body contouring surgical procedures included breast reduction, mastopexy, abdominoplasty/panniculectomy, brachioplasty, and thighplasty. These procedures were identified in the database using CPT codes. (See Table, Supplemental Digital Content 1, which shows the body contouring procedures with CPT codes, http:// links.lww.com/PRS/D153.) Prior bariatric surgery was not required for inclusion in the cohort.
We included only patients with continuous insurance coverage for 12 months before surgery and 6 months after surgery. Patients with hospital length of stay greater than 30 days were excluded to eliminate confounding resulting from severe, unusual postoperative complications. To ensure that patients with opioid use attributable to additional surgical procedures were not included in our cohort, patients with a subsequent anesthesia procedural code in the 6 months after the index surgical procedure were excluded. We also excluded any patients readmitted during the persistent use period (90 to 180 days after surgery), as reason for readmission could not be ascertained and may not reflect opioid use.
To increase the likelihood of an opioid-naive cohort, we limited our analysis only to patients who did not fill an opioid prescription in the 11 months before the perioperative period. The perioperative period was defined as 30 days before to 14 days after discharge. Patients who did not fill an opioid prescription within the defined perioperative period were excluded.
Patient Covariates
Information on patient demographics, socioeconomic status, geographic region of residence, and clinical covariates were included. The Charlson Comorbidity Index score 19 and an indicator for history of tobacco use were used to assess patient comorbid conditions. Mental health conditions were classified as adjustment disorders, anxiety disorders, mood disorders, suicide or self-harm, disruptive disorders, personality disorders, psychosis, other mental health disorders, and alcohol or substance abuse disorders using the Agency of Healthcare Research and Quality Clinical Classification System. 20 (See 
Outcomes
Persistent opioid use was the primary outcome, defined as continued prescription fills between 90 and 180 days after discharge, among those patients who had filled an opioid prescription in the perioperative period. 8 The total quantity of opioids filled by the patient during the perioperative period of 30 days before surgery to 14 days after discharge was converted into oral morphine equivalents using standardized guidelines (e.g., codeine 30 mg = 4.5 oral morphine equivalents, hydrocodone 30 mg = 3 0 oral morphine equivalents, oxycodone 30 mg = 45 oral morphine equivalents). 21 Finally, patterns of highrisk prescribing during the perioperative period were identified within the cohort. High-risk prescribing was defined as at least one of the following: (1) patients with prescriptions from more than one prescriber, (2) patients with prescriptions of more than 100 oral morphine equivalents per day, (3) patients with overlapping opioid and benzodiazepine prescriptions, (4) patients with concurrent opioid prescriptions, and (5) patients with prescriptions for long-acting opioids.
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Statistical Analysis
All analyses were conducted using Stata version 14.2 (StataCorp, College Station, Texas). Descriptive statistics were calculated for demographic variables and comorbidities. Differences between those with persistent opioid use and those without persistent opioid use were assessed with t tests and chi-square tests. A multivariate logistic regression model was used to identify variables associated with both new persistent opioid use and high-risk prescribing, including age, gender, education, household income, U.S. Census Bureau geographic region, surgical procedure, length of stay, Charlson Comorbidity Index, history of tobacco use, mental health disorders, pain disorders, and total opioid prescription oral morphine equivalents within the perioperative window. The p values were two-tailed, and significance was set at p < 0.05. All covariates were evaluated for multicollinearity using variance inflation factors, and we found no significant multicollinearity in the variables included in the regression model.
RESULTS
Our final cohort included 11,257 opioidnaive patients, all of whom filled perioperative opioid prescriptions. Within the cohort, 89.2 percent underwent breast reduction, 6.4 percent underwent mastopexy, 4.1 percent underwent abdominoplasty/panniculectomy, 0.2 percent underwent thighplasty, and 0.1 percent underwent brachioplasty. The mean age of the cohort was 41.0 ± 11.9 years, and the vast majority of patients were Caucasian (70.1 percent) and female (99.1 percent). Back pain and arthritis were present in two-thirds of the cohort (67.8 percent and 65.8 percent, respectively) and neck pain was present in half (52.3 percent), with 42.6 percent of patients carrying some other pain-related diagnosis.
Of 11,257 patients, 690 continued to fill opioid prescriptions more than 3 months after surgery, which constituted 6.1 percent of the cohort. Patients who developed persistent use differed significantly in several variables on bivariate analysis, all of which were controlled for in our regression (Table 1 ). Adjusted new persistent use was highest for patients undergoing thighplasty (17.7 percent), with abdominoplasty/panniculectomy having the second highest rate (8.1 percent) ( Fig. 1 ). Persistent users were also prescribed 300 oral morphine equivalents on average within the perioperative period, whereas nonpersistent users were prescribed 225 oral morphine equivalents (Table 2) . Lastly, high-risk prescribing occurred in 1451 patients, and 9.2 percent (133) of these patients developed persistent use.
After adjusting for significant covariates, neither age, sex, nor education level was significantly associated with persistent opioid use after surgery (Table 3 ). However, compared with patients earning less than $40,000 per year, patients earning more than $40,000 exhibited lower odds of developing persistent use, with incomes $50,000 to 59,000 (OR, 0.54; 95 percent CI, 0.35 to 0.84), $75,000 to $99,000 (OR, 0.60; 95 percent CI, 0.43 to 0.84), and more than $100,000 (OR, 0.62; 95 percent CI, 0.47 to 0.82) exhibiting independent effects. Higher odds of persistent use were also seen in patients from the Mountain (OR, Plastic and Reconstructive Surgery • January 2019 prescribed greater than 337.5 mg oral morphine equivalents (75th percentile) during the perioperative period were more likely to become persistent users than those who were prescribed less than 337.5 mg oral morphine equivalents (OR, 1.53; 95 percent CI, 1.30 to 1.81). 
DISCUSSION
Using administrative claims data, we found that 6.1 percent of body contouring patients were still filling opioid prescriptions more than 90 days after surgery. This rate increased to 9.2 percent with high-risk prescribing, which approached the rates of persistent use among both breast oncology and breast reconstruction patients. 11, 23 Patients who developed new persistent use tended to earn lower incomes, and were more likely to have other pain diagnoses and mental health problems. Being from the Mountain and West South Central divisions of the country was also associated with higher odds of persistent use, which likely affects ongoing practice pattern variations. Moreover, patients with a history of tobacco use, anxiety, and a greater number of comorbidities were at greater risk for persistent opioid use.
Body contouring comprises a large proportion of plastic surgery procedures, with more than 300,000 patients undergoing these operations in the United States last year. 18 A large percentage of patients undergo body contouring for purely cosmetic reasons, but insurance typically covers only procedures deemed medically necessary, often after massive weight loss. 24 The sequelae of massive weight loss include ptotic and atrophied breasts, significant skin redundancy of the abdomen and extremities, and skin breakdown. 25, 26 Patients with redundant skin often have difficulties with exercise, clothes, and self-image, despite considerable weight loss. 27 Unfortunately, these consequences negatively impact both appearance and quality of life for patients who have just gone to great lengths to improve both. 28 Opioid analgesics have been the traditional method of pain control following body contouring procedures, and multimodal anesthesia and opioid alternatives have not been extensively IQR, interquartile range; OME, oral morphine equivalent.
Plastic and Reconstructive Surgery • January 2019 studied. In breast reductions, intraoperative local anesthesia, preoperative pain management, and pain pumps were shown to decrease postoperative opioid use. [29] [30] [31] Holzman et al. advocated for the use of tumescence to promote same-day discharge in abdominoplasty patients, and suggested that opioid use would decrease with tumescence use, although the study did not include a control group. 32 Some surgeons place pain pumps in abdominoplasty patients, which resulted in decreased narcotic use 72 hours postoperatively. 33 Other surgeons perform field blocks, which decrease postoperative opioid consumption, 34 rendered most effective by using a systematic approach that addresses the various manipulated tissue planes. 35 In a review by Vyas et al., blocks using liposomal bupivacaine were found to be both safe and well tolerated in various plastic surgery procedures and functions as a viable alternative to opioids for treating postoperative pain. 36 The cost of such drugs is worth considering, as they may not be cost-effective for all plastic surgery procedures, 37, 38 but the upfront cost may be significantly less than the long-term cost of opioid addiction.
Interestingly, body contouring patients seem to be uniquely predisposed to persistent opioid consumption. A recent study described that 21.1 percent of patients developed persistent postoperative pain after body contouring, 17 for which opioids are not a recommended treatment. 39 Similar to our findings with respect to opioid fills, patients with mood disorders and anxiety were more likely to develop prolonged pain after surgery. 17 More specifically, patients undergoing thighplasties were most likely to develop persistent use. Although studies evaluating the effect of patient demographics and psychiatric comorbidities on pain and recovery are lacking, the rate of complications after thighplasties is high. 40 Complications during the postoperative period, and the unique stress placed on thighplasty wounds from walking and sitting, may result in prolonged pain after surgery.
In this context, consideration of nonopioid pain medications during the perioperative period is critical. Acetaminophen results in improved analgesia when taken in conjunction with narcotics and simultaneously decreases opioid consumption 17 and should be prescribed after plastic surgery procedures. 41 Multiple meta-analyses studying gabapentin and pregabalin concluded that both drugs improve pain control postoperatively and decrease narcotic use, with very acceptable risk-to-benefit ratios. 42 In a systematic review by Kelley et al., ibuprofen was found to provide pain control comparable to narcotics and was not associated with increased bleeding risk in soft-tissue surgery. 43 Another review article discussed the safety of ketorolac in plastic surgery, finding that its perioperative use reduced opioid use and did not result in increased hematoma rates in various plastic surgery procedures. 44 Perhaps most salient is the recommendation to provide multimodal analgesia in body contouring, which can lower the total doses of medications and also shorten discharge times. 45, 46 Considered together, the evidence supports the safe use of opioid alternatives for soft-tissue plastic surgery for postoperative pain control.
To date, although some guidance exists for opioid prescribing in chronic pain, 47, 48 protocols for postoperative prescribing are notably absent. Although not directly addressing postoperative pain, Frieden and Houry suggest that 3 or fewer days of opioids is often sufficient for treating acute pain, and a prescription lasting more than 7 days is seldom required. 48 Interestingly, our findings align with prior work that suggests that opioid doses exceeding the 75th percentile in the perioperative period were associated with a much greater likelihood of persistent use after surgery. 9 Although we cannot assess causality, opioid prescribing in the postoperative period is a critical aspect of care, which may provide early warning signs regarding patients with the potential to go on to new persistent use. Our study sample consisted entirely of opioid-naive patients, but with a high rate of preexisting pain conditions. As such, it is possible that patients continue to use opioids to manage pain other than surgical-site pain in the postoperative period, contributing to new persistent use. 49 Most importantly, we are currently working to develop tailored opioid-prescribing guidelines for various procedures, based on normative opioid consumption, to prevent the development of persistent opioid use in opioid-naive patients.
Our study had several limitations. We were unable to examine all body contouring patients, because administrative claims data can provide information only on procedures covered by insurance, and thus the results cannot be generalized to the entire body contouring population. Also, more granular data surrounding body mass index and preoperative weight loss were unavailable, and thus we could not determine the impact of either covariate on persistent use. Future studies evaluating the relationship between opioid use after bariatric procedures, resultant weight loss, and subsequent body contouring procedures would also be of immense value. In addition, the Plastic and Reconstructive Surgery • January 2019 data could not provide specific measures of acute pain in the perioperative period or more granular aspects of clinical care or patient characteristics that impact opioid use. Technical details of the various procedures also could not be considered. Finally, we do not have information regarding opioid consumption from claims data.
CONCLUSIONS
Persistent opioid use after body contouring occurred in 6.2 percent of patients, most of whom likely underwent these procedures after massive weight loss. High-risk prescribing occurred in 12.9 percent of patients, with 9.2 percent of this subgroup going on to persistent use. Moving forward, it is important for clinicians to be aware of the patient-level factors that increase the risk of persistent use, and avoid high-risk prescribing. States annually. Many of these procedures are performed on individuals who formerly had extreme obesity and have lost a significant amount of their body weight following bariatric surgery. Women and men with extreme obesity often suffer from a wide range of comorbidities, including type 2 diabetes, hypertension, sleep apnea, and depression. Many suffer with chronic pain that impairs their daily functioning and quality of life. Most patients manage the symptoms of these conditions with medications. Encouragingly, many of these comorbidities improve following significant weight loss and many patients are able to reduce their reliance on medications to manage their symptoms. Others, however, continue to use these medications postoperatively to manage their comorbidities.
Substance misuse among persons with obesity who undergo bariatric surgery has been of great interest over the past decade. In general, this population of patients has a higher lifetime rate of substance use disorders compared with the general population. Active substance abuse is a contraindication to bariatric surgery, so rates of substance misuse at the time of surgery are low. Alcohol and substance use and misuse remain low during the first postoperative year. However, both gradually increase each postoperative year. In addition, a small percentage of patients without a history of substance misuse start misusing substances following bariatric surgery, typically alcohol and opioids.
The observations of Bennett and colleagues from a large sample of insurance claims data from body contouring patients largely replicate this pattern of substance misuse. The focus on opioids is particularly relevant given the epidemic nature of the problem throughout the United States. In this study, 6.1 percent of individuals who were not misusing opioids prior to body contouring appeared to be doing so postoperatively. Approximately 13 percent were exposed to high-risk prescribing by providers, putting them at risk for misuse and abuse. Not surprisingly, those with previous issues with pain, as well as those with mood disorders or anxiety, were most likely to engage in persistent use.
The use of a large, nationwide data set, rather than reliance on data from a single institution or health system, increases the confidence that can be placed in the findings. As noted by the authors, the study also has limitations. While use of insurance claims data typically allows for large sample sizes, it often lacks in more granular data that are routinely found in medical records or obtained by validated patient-reported outcome measures, which are being used with greater frequency in the plastic surgery literature.
These findings have important clinical implications. Given these observations, as well as the parallel findings from the bariatric literature summarized above, the plastic surgery team is encouraged to assess the history of substance use and abuse in patients who present for body contouring procedures. Bariatric surgery patients are told to avoid alcohol and other substances postoperatively, but it is clear that a INSIGHTS PSYCHOSOCIAL minority of patients, those both with and without a history of substance misuse, struggle to do so. As noted by the authors, opioid prescription guidelines are lacking. In the absence of those guidelines, plastic surgeons are encouraged to thoughtfully consider the use of opioids following a body contouring procedure and be mindful of the potential for misuse. Disclosure: Dr. Sarwer currently has grant funding in the area of bariatric surgery from the National Institute of Diabetes, Digestive, and Kidney Disease (R01-DK-108628-01) as well as from the Commonwealth of Pennsylvania (PA CURE). He also is a member of the Board of Directors of the American Board of Plastic Surgery and the Aesthetic Surgery Education and Research Foundation. He has consulting relationships with BARONova, Merz, and Novo Nordisk.
